On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). RELIEVE UCCD investigated duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for moderate-to-severe inflammatory bowel disease (IBD). In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of pati…

Benzinga

New York

United States

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? - Teva Pharmaceutical Indus (NYSE:TEVA), Sanofi (NASDAQ:SNY)

Ad Fontes Media

Media Bias/Fact Check

Teva (TEVA) stock and Sanofi (SNY) stock jump after a mid-stage trial win for an experimental antibody therapy targeting inflammatory bowel diseases. Read more here.

Seeking Alpha

Teva stock gains after mid-stage IBD trial win (TEVA:NYSE)

Teva and Sanofi's Phase 2b RELIEVE UCCD study shows duvakitug improves remission in ulcerative colitis and response in Crohn's disease.This article …

Cryptocurrency News | Cryptocurrency Prices | Market Cap

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

Teva reported that the trial for Dukaviyug, which it is developing with Sanofi, met its endpoints in ulcerative colitis and Crohn's disease.

Globes

Teva jumps sharply on bowel disease drug results

The Teva Pharmaceuticals and Sanofi drug, duvakitug, showed statistically significant and clinically meaningful results in a Phase 2b study in ulcerative colitis and Crohn’s disease. The drug is part of an emerging class of therapies that target TL1A, a protein involved in signaling that drives inflammation.  The post Teva and Sanofi Mid-Stage Data Reveal Shows Best-in-Class Potential for IBD Drug appeared first on MedCity News.

MedCity News

Teva and Sanofi Mid-Stage Data Reveal Shows Best-in-Class Potential for IBD Drug

Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibody Sanofi and Teva plan to initiate phase 3 development in IBD, pending regulatory discussions Program underscores Sanofi’s Immunology leadership ambition  PARIS, France and Parsippany, NJ, USA I Decemb…

pipelinereview

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease - Pipelinereview

Singular Market Consensus Bank  The pharmaceuticals Teva and Sanofi today recorded significant progress after announcing the positive results of clinical tests of their drug Duvatikug for the treatment of intestinal inflammation. According to published results, for patients with ulcerative colitis who have taken a small dose 36% have reached clinical remission, and with a dose greater than 50%. This compares with a remission of 20% in patients w…

Consenso del Mercado Singular Bank | Las farmacéuticas Teva y Sanofi registraban hoy avances significativos tras anunciar los resultados positivos de pruebas clínicas de su fármaco Duvatikug para el tratamiento de la inflamación intestinal. De acuerdo con los resultados publicados, para pacientes con colitis ulcerosa que han tomado una dosis pequeña el 36% han alcanzado la remisión clínica, y con una dosis mayor el 50%. Esto compara con una remi…

Noticias Bolsas internacionales Resultados positivos para Teva y Sanofi en las pruebas clínicas de su fármaco para el tratamiento de la inflamación intestinal, Duvatikug

Consenso del Mercado

News International bags Positive results for Teva and Sanofi in clinical trials of their drug for the treatment of intestinal inflammation, Duvatikug

Check out the companies making headlines in afternoon trading: Teva Pharmaceuticals, Sanofi – Shares of Teva Pharmaceuticals and Sanofi rose more than 26% and 6%, respectively, after the companies announced positive Phase 2b results for duvakitug, their joint treatment from moderate to severe inflammatory bowel disease. Pfizer – Shares traded more than 4% higher after […]

Daily Expert News

Stocks making the biggest moves in the afternoon: Pfizer, Broadcom, Teva Pharmaceuticals and more

Teva Pharmaceuticals (NASDAQ: TEVA) and its partner Sanofi (NASDAQ: SNY) have announced groundbreaking results from clinical trials of their drug, duvakitug, for ulcerative colitis and Crohn’s disease, two of the most prevalent forms of inflammatory bowel disease (IBD).  The announcement, which sent Teva’s stock soaring by 26.4% to $20.88 and Sanofi’s up 6.7% to $48.94, marks a significant milestone in IBD treatment development. Promising trial …

Invezz

TEVA stock soars 26%: What’s going on with Teva Pharmaceuticals?

Teva Announces Excellent Results in Phase 2 Clinical Trial of Drug for Ulcerative Colitis and Crohn's Disease, With Potential Market of $28 Billion; Teva Stock Jumps More Than 7% Pre-on Wall Street Following Announcement

טבע הודיעה על תוצאות מצוינות בניסוי קליני שלב 2 בתרופה למחלות קוליטיס כיבית ומחלות קרוהן, עם שוק פוטנציאלי של 28 מיליארד דולר; מניית טבע קופצת ביותר מ-7% בטרום בוול סטריט בעקבות ההודעה

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? - Teva Pharmaceutical Indus (NYSE:TEVA), Sanofi (NASDAQ:SNY)

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics